These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Transthyretin-related hereditary amyloid polyneuropathy presenting with large fibre involvement and cardiomyopathy. Cruz S; Cortes-Vicente E; Illa I; Rojas-Garcia R Amyloid; 2016; 23(1):64-5. PubMed ID: 26806028 [No Abstract] [Full Text] [Related]
45. Unravelling the colourful tapestry of hereditary transthyretin amyloid polyneuropathy in Poland. Mauricio EA Neurol Neurochir Pol; 2020; 54(6):486-487. PubMed ID: 33400257 [No Abstract] [Full Text] [Related]
46. Potential use of glucuronylglucosyl-β-cyclodextrin as a novel therapeutic tool for familial amyloidotic polyneuropathy. Jono H; Anno T; Motoyama K; Misumi Y; Tasaki M; Oshima T; Mori Y; Mizuguchi M; Ueda M; Shinriki S; Shono M; Obayashi K; Arima H; Ando Y Amyloid; 2012 Jun; 19 Suppl 1():50-2. PubMed ID: 22620966 [TBL] [Abstract][Full Text] [Related]
47. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570 [TBL] [Abstract][Full Text] [Related]
48. Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy. Müschen LH; Körner G; Gingele S; Hänselmann A; Bavendiek U; Skripuletz T Muscle Nerve; 2021 Sep; 64(3):E11-E13. PubMed ID: 34075597 [No Abstract] [Full Text] [Related]
49. Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Benson MD; Dasgupta NR; Rissing SM; Smith J; Feigenbaum H Amyloid; 2017 Dec; 24(4):219-225. PubMed ID: 28906150 [TBL] [Abstract][Full Text] [Related]
50. Amyloid Polyneuropathy and Myocardial Amyloidosis 10 Years after Domino Liver Transplantation from a Patient with a Transthyretin Ser50Arg Mutation. Matsushima M; Yabe I; Tsuda M; Sakakibara M; Shimamura T; Sasaki H Intern Med; 2017 Dec; 56(23):3231-3235. PubMed ID: 28943540 [TBL] [Abstract][Full Text] [Related]
55. Transthyretin Val30Met familial amyloid polyneuropathy: a considerably different clinical picture and natural course in endemic and non-endemic areas. Ikeda S J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):121. PubMed ID: 22228783 [No Abstract] [Full Text] [Related]
56. VIth International Symposium on Familial Amyloidotic Polyneuropathy and other Transthyretin Disorders and the Vth International Workshop on Liver Transplantation in Familial Amyloidotic Polyneuropathy 24-26 August 2005 La Jolla, CA, USA. Buxbaum JN Amyloid; 2006 Jun; 13(2):111-3. PubMed ID: 16911966 [No Abstract] [Full Text] [Related]
58. Effects of liver transplantation and tafamidis in hereditary transthyretin amyloidosis caused by transthyretin Leu55Pro mutation: a case report. Kon T; Misumi Y; Nishijima H; Honda M; Suzuki C; Baba M; Inomata Y; Obayashi K; Ando Y; Tomiyama M Amyloid; 2015; 22(3):203-4. PubMed ID: 26123280 [No Abstract] [Full Text] [Related]
59. Transthyretin ALA 71: a new transthyretin variant in a Spanish family with familial amyloidotic polyneuropathy. Almeida Mdo R; Lopez-Andreu F; Munar-Qués M; Costa PP; Saraiva MJ Hum Mutat; 1993; 2(5):420-1. PubMed ID: 8257997 [No Abstract] [Full Text] [Related]